Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) traded down 2.8% during mid-day trading on Monday . The stock traded as low as $2.81 and last traded at $2.80. 1,544 shares were traded during trading, a decline of 100% from the average session volume of 1,534,396 shares. The stock had previously closed at $2.88.

The firm has a market capitalization of $4.40 million, a PE ratio of -0.10 and a beta of 1.85.

Several institutional investors and hedge funds have recently added to or reduced their stakes in TNXP. Citigroup Inc. acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth $34,000. CVI Holdings LLC bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth $36,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth $38,000. 34.30% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Tonix Pharmaceuticals (TNXP) Trading Down 2.8%” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.thecerbatgem.com/2019/03/18/tonix-pharmaceuticals-tnxp-trading-down-2-8.html.

Tonix Pharmaceuticals Company Profile (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.

Featured Story: Fundamental Analysis and Choosing Stocks

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.